Medicines
Medicines Built on
Trust & Evidence
GMP-sourced, licensed medicines distributed across UK and international markets — precision formulations physicians and patients rely on.
A widely used first-line PPI that reduces stomach acid by irreversibly blocking the H⁺/K⁺-ATPase proton pump. Metabolised via CYP2C19 and available in both prescription and OTC strengths for short-term heartburn relief. Suitable for broad GI indications.
A PPI with more predictable pharmacokinetics than omeprazole, metabolised via CYP2C19 and CYP3A4 with a lower potential for drug interactions. The preferred choice for patients on anticoagulants, antiplatelet therapy, or complex polypharmacy regimens.
Omeprazole vs Pantoprazole
A clinical reference for prescribers, pharmacists and procurement teams.
| Property | Omeprazole | Pantoprazole |
|---|---|---|
| Drug Class | Proton Pump Inhibitor (PPI) | Proton Pump Inhibitor (PPI) |
| Mechanism | Irreversible H⁺/K⁺-ATPase inhibition in gastric parietal cells | Irreversible H⁺/K⁺-ATPase inhibition in gastric parietal cells |
| Metabolism | CYP2C19 (variable — polymorphic) | CYP2C19 + CYP3A4 (more predictable) |
| Half-Life | ~1–1.5 hours | ~1 hour |
| Available Strengths | 20 mg, 40 mg (capsules & oral suspension) | 40 mg (tablets & oral suspension) |
| Drug Interactions | Higher risk — inhibits CYP2C19; interacts with clopidogrel, warfarin, methotrexate Caution | Lower risk — fewer CYP enzyme interactions; preferred with polypharmacy Preferred |
| OTC Available | Yes — for short-term heartburn (20 mg) | No — prescription only |
| Preferred For | First-line, broad GI use, H. pylori regimens | Patients on anticoagulants or multiple medications |
| Pack Size | 3 × 10 Capsules / Tablets | 3 × 10 Tablets |
| Supply | Wholesale & export available | Wholesale & export available |
Wholesale & Export Enquiries
Contact our team for pricing, regulatory documentation, or distribution partnerships.